Catherine L Clelland - JoVE Visualize

Showing results (1-10 of 11) with videos related to

Pageof 2

Sort By:

Bjpsych Open|June 18, 2026

Psychedelics, the media portrayal and large-language model evaluationsCatherine L Clelland

Bjpsych Open|December 3, 2021

Analysis of the impact of antidepressants and other medications on COVID-19 infection risk in a chronic psychiatric in-patient cohortCatherine L Clelland, Krista Ramiah, Louisa Steinberg, et al.

Psychiatry Research|February 23, 2018

Regulation of cortical and peripheral GCH1 expression and biopterin levels in schizophrenia-spectrum disordersJames D Clelland, Laura L Read, Jennifer Smeed, et al.

Translational Psychiatry|October 2, 2024

The relationship between COMT, proline, and negative symptoms in clinical high risk and recent psychosis onsetJames D Clelland, Hannah Hesson, Krista Ramiah, et al.

Plos One|July 5, 2013

Utilization of never-medicated bipolar disorder patients towards development and validation of a peripheral biomarker profileCatherine L Clelland, Laura L Read, Laura J Panek, et al.

Nature Medicine|December 23, 2015

Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signalingNatura Myeku, Catherine L Clelland, Sheina Emrani, et al.

Schizophrenia Research|May 3, 2014

Vitamin D insufficiency and schizophrenia risk: evaluation of hyperprolinemia as a mediator of associationJames D Clelland, Laura L Read, Valérie Drouet, et al.

Schizophrenia Research|June 8, 2011

Evidence for association of hyperprolinemia with schizophrenia and a measure of clinical outcomeCatherine L Clelland, Laura L Read, Amanda N Baraldi, et al.

Science Translational Medicine|May 27, 2021

PAC1 receptor-mediated clearance of tau in postsynaptic compartments attenuates tau pathology in mouse brainAri W Schaler, Avery M Runyan, Catherine L Clelland, et al.

Bjpsych Open|December 15, 2025

A proof-of-concept study: investigating the impact of COMT genotype and proline on negative symptoms in Alzheimer's diseaseJames D Clelland, Hector W Cure, Ashley M Canizares, et al.

Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:

Pageof 2

Bjpsych Open|June 18, 2026

Psychedelics, the media portrayal and large-language model evaluationsCatherine L Clelland

Bjpsych Open|December 3, 2021

Analysis of the impact of antidepressants and other medications on COVID-19 infection risk in a chronic psychiatric in-patient cohortCatherine L Clelland, Krista Ramiah, Louisa Steinberg, et al.

Psychiatry Research|February 23, 2018

Regulation of cortical and peripheral GCH1 expression and biopterin levels in schizophrenia-spectrum disordersJames D Clelland, Laura L Read, Jennifer Smeed, et al.

Translational Psychiatry|October 2, 2024

The relationship between COMT, proline, and negative symptoms in clinical high risk and recent psychosis onsetJames D Clelland, Hannah Hesson, Krista Ramiah, et al.

Plos One|July 5, 2013

Utilization of never-medicated bipolar disorder patients towards development and validation of a peripheral biomarker profileCatherine L Clelland, Laura L Read, Laura J Panek, et al.

Nature Medicine|December 23, 2015

Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signalingNatura Myeku, Catherine L Clelland, Sheina Emrani, et al.

Schizophrenia Research|May 3, 2014

Vitamin D insufficiency and schizophrenia risk: evaluation of hyperprolinemia as a mediator of associationJames D Clelland, Laura L Read, Valérie Drouet, et al.

Schizophrenia Research|June 8, 2011

Evidence for association of hyperprolinemia with schizophrenia and a measure of clinical outcomeCatherine L Clelland, Laura L Read, Amanda N Baraldi, et al.

Science Translational Medicine|May 27, 2021

PAC1 receptor-mediated clearance of tau in postsynaptic compartments attenuates tau pathology in mouse brainAri W Schaler, Avery M Runyan, Catherine L Clelland, et al.

Bjpsych Open|December 15, 2025

A proof-of-concept study: investigating the impact of COMT genotype and proline on negative symptoms in Alzheimer's diseaseJames D Clelland, Hector W Cure, Ashley M Canizares, et al.

Pageof 2